Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01568632|
Recruitment Status : Withdrawn
First Posted : April 2, 2012
Last Update Posted : November 21, 2012
- Imetelstat is a cancer treatment drug that may slow or stop tumor growth. It may also prevent tumors from spreading to other parts of the body. Researchers want to see if it can be a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments.
- To see if imetelstat is a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments.
- Children and adolescents between 1 and 21 years of age who have solid tumors or lymphoma that have not responded to other treatments.
- Participants will be screened with a physical exam, medical history, and imaging studies. Blood and urine samples will also be collected.
- Participants will receive imetelstat on the first and eighth day of a 21-day cycle of treatment.
- Treatment will be monitored with frequent blood tests and imaging studies. Tumor biopsies may also be performed.
- Participants will keep taking the study drugs for up to a total of 18 cycles as long as the disease does not progress and there are no severe side effects....
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors Lymphoma||Drug: Imetelstat||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas|
|Study Start Date :||March 2012|
|Actual Study Completion Date :||October 2012|
- Estimate the maximum tolerated dose (MTD) of imetelstat given as a 2-hour IV infusion on D1 and D8 every 21 days.
- Define the toxicities and characterize pharmacokinetics
- To define antitumor effects and to assess the biological activity by assessing telomerase activity, telomere length, hTERT protein, hTERT mRNA and hTR levels; hTERT expression and protein, telomere length, hTERT mRNAS and hTR levels in tumor.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01568632
|Principal Investigator:||William L Dahut, M.D.||National Cancer Institute (NCI)|